When you have decided a biologic is the next step
Consider ENBREL for Patients with Moderate to Severe RA

ENBREL is indicated for reducing signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.1

Learn more about the efficacy of ENBREL from a leading rheumatologist


Rapid, Sustained Efficacy of ENBREL

Review the rapid and sustained efficacy of ENBREL with KOL, Dr. Fleischmann.

Watch video

ENBREL demonstrated significant and sustained efficacy

Across clinical studies, ENBREL demonstrated efficacy in patients with moderate to severe RA1-4:

Improved clinical
signs and symptoms

See change from baseline in pain, morning stiffness, and CRP.

View Data

Improved
physical function

See reductions in HAQ scores.

View Data

Sustained
clinical remission

See percentage of patients achieving DAS 28 clinical remission.

View Data

Inhibited progression of
joint damage

See changes in mTSS across clinical studies.

View Data

The risk of progressive structural damage is high in patients with moderate to severe RA. Structural damage may still be occurring in your RA patients despite clinical improvements with MTX alone. Adding ENBREL to MTX in moderate to severe RA has been shown to be significantly more effective than MTX alone in helping to stop progressive joint damage.
 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

Introducing ENBREL Nurse Partners

Dedicated registered nurses are now available to give your patients the personal assistance
they need.

Here's how they can help
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years